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Autism spectrum disorder 
Sana Mubashir, Matthias Farrugia, Lorena Coretti, Mauro Pessia, Maria Cristina D’Adamo
    Autism spectrum disorder (ASD) is a complex heterogeneous 
condition that is characterized by impairments in social interaction, 
communication, and behaviour which mostly co-exist with several 
comorbidities. The current prevalence of ASD in the general 
population is estimated to be that of 1 in every 54 children in USA. 
The accurate diagnosis involves detailed assessments at age specific 
intervals and finally a comprehensive evaluation by specialists. 
Although genetic and environmental factors contribute to cause 
ASD, the precise mechanisms underlying ASD are poorly understood.  
Concerning management, early interventions are always 
recommended, as they lead to better outcomes. However, despite 
the availability of multiple medications, no definitive cure currently 
exists and the management of the disease remains poor, posing 
significant problems to life perspectives. Therefore, further studies 
are required to fully understand the pathogenesis and the possible 
resultant identification of more effective treatment options for ASD. 
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INTRODUCTION 
ASD is a complex and heterogeneous 
neurodevelopmental disorder, which 
manifests itself with a variety of signs and 
symptoms.1 The Diagnostic and Statistical 
Manual of Mental Disorders (DSM V) defines 
ASD as an incessant neurodevelopmental 
disorder that exhibits poor social skills, 
essentially in terms of social-emotional 
reciprocity, verbal and non-verbal 
communication along with restrictive and 
repetitive behaviour which are present from 
early developmental age.  According to DSM V, 
several related diseases such as Asperger’s 
disorder, childhood disintegrative disorder 
also known as Heller syndrome or pervasive 
developmental disorder, which are not 
otherwise specified and, others are now 
diagnosed as ASD. However, the notion that 
mental disorders can be classified into distinct, 
discrete categories has been challenged and 
scientists are re-examining the theories 
underlying brain illnesses, significantly. 
Indeed, it appears that these disorders shade 
into each other, as there are no hard dividing 
lines and, changes in the brain’s decision-
making systems could be involved in many 
different conditions. This new perspective is 
further supported by genetic evidences 
showing that the same genes are associated 
with seemingly distinct disorders, such as 
autism and schizophrenia.2-3  
It has been proposed that the use of new 
diagnostic criteria could be responsible for the 
rise in the number of cases of autism, rather 
than a true rise in the prevalence of the 
disorder.4,5 However, it seems unlikely that this 
assumption could account for the diagnosis of 
a child with autism with every 54 new-born in 
US6 and the higher incidence rates reported in 
distinct countries such as Hong Kong and 
Japan.  Psychiatrists have long observed 
differences also between women and men in 
terms of their susceptibility to certain brain 
disorders. Autism is among those, as boys are 
more affected than girls (4:1 ratio)7 and  
females are diagnosed with ASD at later age 
compared to males.8 Interestingly, it has been 
reported that  estrogens can rescue ASD 
phenotypes in animal models of autism 
supporting the “female protective theory”.9 
To address ASD-related issues and compile this 
review we selected the literature published 
from 1995 till 2020 using the PubMed, Scopus 
and Google Scholar databases and the 
keywords autism spectrum disorder, etiology, 
diagnosis and treatment. Particular emphasis 
was given to the evaluation of evidence based 
research and clinical practice trough 
systematic review of high quality publications.  
PRESENTATION 
The presentation of ASD tends to vary from 
one individual to another. This variation in the 
clinical symptoms could be explained by 
alterations in the heritable background, 
epigenetics, and environmental factors.10 The 
following three main core symptoms should be 
observed to enable one to properly diagnose 
ASD in a subject: (a) continuous difficulty in 
communication and interaction which are 
social and reciprocal; (b) difficulty in using or 
understanding language, tending to focus 
attention and conversation on a limited 
number of topics, frequently repeating 
phrases, and have very limited speech ability; 
(c) restrictive and repetitive behavior. The 
severity of ASD can be graded from Level 1 to 
Level 3 in two domains: social communication 
and restrictive stereotyped behaviour. 
Regarding communication, severity ranges 
from problems with starting social interactions 
to verbal and non-verbal communication 
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resulting in impaired functioning. Concerning 
behavioural deficits, the phenotype can range 
from the inflexibility of behaviour in one 
context to extreme difficulty in coping with 
changes in daily routine, significantly 
interfering with proper functioning in all 
spheres.11 Autism coexists with other 
disorders in nearly 95% of the cases and its 
occurrence alone is rare. Indeed, several 
comorbidities are often associated with ASD 
such as epilepsy (up to 30%), intellectual 
disability (~40%), sleep disorders (50–80%), 
gastrointestinal problems (up to 70%) and 
motor deficits (~80%). 
SCREENING AND DIAGNOSIS 
The American Academy of Pediatrics (AAP) 
policy recommends surveillance and screening 
to identify children who are at a risk of ASD at 
an earlier stage to ensure implementation of 
the effective interventions. The guidelines 
recommend developmental surveillance at 9, 
15 and 30 months of age and specific screening 
for autism at 18, 24 and 30 months of age.12-13 
Surveillance includes: a) maintaining a 
developmental history; b) making accurate and 
informed observations of the child; c) eliciting 
and attending to parents' concerns; d) 
identifying the presence of risk and protective 
factors; e) documenting the process and 
findings. It should be performed at every 
preventive visit throughout childhood. Further 
standardized developmental tools should be 
used for screening if surveillance raises 
concerns. Notably, the AAP recommends that 
all children should be screened during visits to 
a primary care provider in an outpatient 
setting with the same time schedule, 
regardless of whether any concerns have been 
raised or not. The screening of the general 
pediatric population is essential to the timely 
identification of children at risk or exhibiting 
signs suggestive of ASD. In addition, AAP 
recommends using a standardized autism-
specific screening tool on all 18-month old 
children at a preventive care visit with 
repeated evaluations for those who regress 
after the initial screening.14 Selection of the 
autism-specific screening tool is done 
according to the age of the child. If the 
screening raises concerns, a referral specialist 
(pediatric neurologist, developmental-
behavioural pediatrician, child psychiatrist, 
licensed child psychologist) should be 
consulted for a definitive diagnosis and 
comprehensive assessment.15 The 
comprehensive examination includes: a) 
detailed pediatric history along with parental 
concerns; b) physical examination including 
assessment for dysmorphic features, head 
circumference, Wood’s lamp examination of 
the skin (tuberous sclerosis) and full 
neurologic examination; c) direct observation 
of the child’s current cognitive, language, and 
adaptive functioning by a clinician experienced 
with ASD according with the DSM V criteria.16 
However, making an ASD diagnosis is just the 
beginning. Further in-depth evaluations 
should be performed to understand the child’s 
unique strengths and challenges. This 
evaluation is crucial for defining what kinds of 
medication, educational programs and 
behavioral therapies would be most beneficial. 
Usually, this process involves a number of 
specialists, such as child neurologists, 
developmental behavioral pediatricians, 
speech-language pathologists, child 
psychologists and psychiatrists, nurse 
practitioners, educational specialists and 
occupational therapists.  
GENETIC FACTORS 
Over the last few decades, it has been shown 
that the genetic component of ASD can range 
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from 40 to 80%.3,17 Large variation in the 
genetic mechanism underlying ASD exists 
depending on the inheritance pattern, 
chromosomal aberration and mode of 
action.18-20 The advanced paternal age has 
been implicated in neurodevelopmental 
disorders due to increased mutation 
occurrence in spermatogenesis at a later 
age.21-22 A seminal study performed by Filstein 
and Rutter showed that monozygotic twins 
had a concordance of 36% meaning that over a 
third of both pairs had autism while no 
concordance was found between dizygotic 
twins. More recently concordance of ~60% has 
also been reported.3 A Swedish study 
demonstrated that monozygotic co-twin 
always had another neurodevelopmental 
disorder disconcordant for ASD.23  It is 
proposed that more than half of the risk of 
developing ASD is linked with genetic 
variability that is evident by an increased 
prevalence of ASD in families of individuals 
with autism.24 Notably, these genes are also 
found in other neurodevelopmental and 
psychiatric disorders.25 To date, hundreds of 
risk genes have been identified by means of 
large-scale genetic screenings of ASD patients 
and their family members.3  The majority of 
reproducible hits point to proteins involved in 
synapse pathology (synapse formation and 
transmission), transcriptional regulation, 
chromatin-remodeling pathways and neural 
network formation (e.g. neuroligins, cadherins, 
synaptic vesicle cycling proteins synapsin-1 
(SYN1), synapsin-2 (SYN2), MeCP2, UBE3A, 
FMRP, FXRP1, SHANK3, GABRG3, etc). Genetic 
defects in sodium, calcium and potassium 
channel types plays an important role in the 
pathogenesis of autism (e.g. SCN2A, CACNA1E, 
KCNJ10, KCNQ3, KCNQ5, KCND2)26. 
Investigations carried out at the University of 
Malta showed that dysfunction of the 
inwardly-rectifying potassium channels Kir4.1 
results in autism associated with epilepsy 
(autism-epilepsy phenotype, AEP) 26-29. Indeed, 
an international collaborative research team 
identified germline heterozygous variants in 
some affected children where epileptic spasms 
were major issues emphasizing the role of 
variants in KCNJ10 (Kir4.1) and KCNJ2 (Kir2.1) 
in AEP.30-32 In the previous seminal studies the 
functional properties of Kir4.1 mutant channel 
were characterized demonstrating that the 
identified mutations produced gain of channel 
function.31 In another study on monozygotic 
twins with autism and short QT interval on ECG 
as a comorbidity, it was demonstrated the 
presence of a novel KCNJ2 variant that 
increased the surface expression of Kir2.1 
channels (gain of function). This study pointed 
to the involvement of Kir2.1 channels in AEP 
and the necessity to perform neuropsychiatric 
assessments in patients with short QT 
syndrome (SQT3) to identify the presence of 
subtle autistic traits.32 Recordings from 
surgical specimens of patients with intractable 
epilepsies showed a remarkable reduction of 
Kir conductance in astrocytes, impairing their 
ability to perform potassium clearance. It 
could be inferred that either the enhancement 
or the reduction of Kir4.1 activity leads to 
epilepsy possibly causing an alteration in the 
excitatory-inhibitory balance in the brain. 
Nevertheless, the mechanisms involved in this 
apparently contradictory dual effect is 
unclear.33 Scientists from the Department of 
Physiology & Biochemistry at the University of 
Malta have contributed prominently to these 
discoveries and are currently clarifying the 
mechanisms responsible for the development 
of AEP that may render valuable benefits to 
autistic individuals. Indeed, a genetically 
modified mouse model of autism was 
generated and is currently under 
investigations in the above mentioned 
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laboratories to further understand the 
pathogenic relevance of KCNJ10 mutations, 
clarify the underlying mechanisms and identify 
potential treatments.  
ENVIRONMENTAL FACTORS 
The possibility that the environment 
contributes to the causation of autism has 
arisen from our current understanding of the 
exquisite vulnerability of the developing 
human brain to toxic substances in the 
environment and studies that specifically 
linked autism to prenatal exposures to 
environmental factors or medicines.34 The 
antiepileptic medication Valproic acid 
represents the typical example of drug-
induced autism which does so through 
different mechanisms.3  Hallmayer and 
colleagues showed that a moderate genetic 
component combined with considerable 
environmental factors may cause ASD.35 In 
terms of maturity, preterm infants are at 
greater risk of adverse neurodevelopmental 
outcomes in comparison to the full term 
infants. Thus, it is recommended that 
premature individuals should be closely 
observed in order to implement effective 
interventions if the need arises.36 The 
proposed factors that may play major roles 
include hypoxia, oxidative stress, 
inflammation, endocrine disturbance and 
immune activation. Several autoantibodies 
such as anti-MAP2, anti-MBP, anti-NFP, anti-
MAG and anti-Tau were found in higher levels 
in children exhibiting ASD with their mothers 
having similar levels. In contrast, control 
children and their mothers had negligible 
amounts of auto-antibodies against neuronal 
and glial proteins, implying the involvement of 
the maternal immune system in the 
development of ASD in offspring.37 Maternal 
intake of folic acid during perinatal period 
reduces the risk for the development of ASD. 
Also, maternal intake of polyunsaturated fatty 
acids decreases the risk for ASD, whereas, very 
low levels of Omega 3 fatty acids increase the 
risk for ASD.35,38 Heavy metals may else play an 
important role in autism. Indeed, newborns 
from mothers exposed to high levels of 
mercury, lead, nickel, and manganese were at 
higher risk of developing autism.39 The risk for 
ASD was doubled by gestational exposure to 
nitrogen dioxide (NO2), particulate matter less 
than 2.5 (PM 2.5) or 10 (PM 10) micrometers in 
diameter.40   In Malta, high concentrations of 
airborne PM are reported particularly in heavy-
traffic areas with the consequent relevant 
health implications.41 Organochlorine 
exposures in the first trimester of gestation 
showed a strong association with ASD. 
Whereas, exposures to pyrethroid or 
bifenthrin during the overall gestational 
period showed moderate association.42  The 
observed heterogeneity in symptoms severity 
and prognosis of ASD patients also suggests 
that a combination of genetic predisposition, 
gut microbiota (GM) dysbiosis and, the 
alteration of metabolites produced by 
microbes may represent a critical 
“environmental factor” impacting  brain 
function and behaviour, thus potentially 
promoting the development of autism.1 
Several observations strongly support the role 
of GM in ASD, such as the high occurrence of 
gastrointestinal (GI) abnormalities in ASD 
patients, the amelioration of symptoms upon 
short-term treatment with antibiotics and 
probiotics and the improvement of GI function 
and behaviour in autistic children after Fecal 
Microbiota Transplant (FMT).43-48 Abnormal 
GM composition has been widely reported 
both in animal models with behavioral traits 
relevant to autism and in human pre-clinical 
investigations of autistic patients.49-52 
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TREATMENT 
In spite of considerable economic costs caused 
by autism, there are limited treatment options 
to ameliorate the typical symptoms associated 
with ASD, and the relevant comorbidities 
known to exacerbate the severity of the 
phenotype. There are numerous challenges for 
the identification of effective treatments for 
ASD. Systematic reviews highlighted the 
possibility that the high heterogeneity in the 
genetic, environmental, cognitive, social and 
ASD phenotype reduce the overall validity and 
efficacy of potential interventions.53 
Anthropological differences, which propose 
the deviation from typical behaviour in one 
culture but not in another culture, further 
contribute to obscure treatment strategies.54 
Aripiprazole and Risperidone are the most 
widely studied medications used to manage 
behavioral symptoms. Aripiprazole, is an 
atypical antipsychotic drug.55 The US FDA 
particularly indicated aripiprazole and 
risperidone for children and approved them 
for the treatment of behaviours associated 
with ASD.56 Such medications control 
irritability, aggressive and self–injury 
behaviours.57-58 Despite some beneficial 
effects, these drugs present with adverse 
effects such as extrapyramidal symptoms, 
tremors and sedation.59 Parents and health 
care professionals must closely monitor a 
child's progress and reactions while he or she 
is taking a medication to be sure that any 
negative side effects of the treatment do not 
outweigh the benefits. Apart from 
medications, early intensive behavioral 
therapy is considered to be beneficial for 
school-aged children diagnosed with ASD.60  
Behavioral interventions can be classified as 
early intensive behavioral and developmental 
interventions, social skills interventions, 
parent training, play/interaction-focused 
interventions, interventions targeting 
symptoms commonly associated with ASD 
such as anxiety, and other general behavioral 
approaches. The Agency for Healthcare 
Research and Quality (United States) reviewed 
several studies reporting statistically 
significant evidence and showed that early 
intensive behavioral therapy over extended 
timeframes was associated with improvement 
in cognitive functioning and language skills of 
young children with ASD. A notable treatment 
approach that is used in many schools and 
treatment clinics for people with ASD is called 
applied behaviour analysis (ABA) which uses 
principles and techniques to understand, treat 
and prevent challenging behaviors such as 
anxiety and to promote new, desired 
behaviors. There are different types of ABA: A) 
Discrete Trial Training (DTT) that uses a series 
of trials to teach each step of a desired 
behavior or response. Lessons are broken 
down into their simplest parts and positive 
reinforcement is used to reward correct 
answers and behaviors. Incorrect answers are 
ignored; B) Early Intensive Behavioral 
Intervention (EIBI) that is used for ASD children 
younger than five, and often younger than 
three; C) Pivotal Response Training (PRT) that 
aims to increase a child's motivation to learn, 
monitor his own behavior, and initiate 
communication with others; D) Verbal 
Behavior Intervention (VBI) that focuses on 
teaching verbal skills. The interventions used 
in the early intensive behavioural therapy are 
outlined in the University of California, Los 
Angeles (UCLA)/ Lovaas-based approach, the 
Early Start Denver Model (ESDM), and parent 
training approach.61 The UCLA/ Lovaas-based 
approach applies ABA procedures that focus 
on teaching new skills and reducing interfering 
behavior in children with ASD. It relies on one-
on-one therapy sessions where a trained 
therapist adopts discrete teaching trials with a 
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child to practice target skills. The therapy is 
tailored to each individual in order to benefit 
the needs of the child.62 The ESDM is an 
approach for preschool-aged autistic children 
that incorporate ABA with developmental and 
relationship-based approaches. This therapy is 
delivered by trained therapists and parents.63 
The Building Block program provides early 
interventions for young children with autism 
and their families. The Building Block model 
includes various approaches such as positive 
behavior support, naturalistic play-based 
intervention, assessment of sensory 
processing issues, and extensive use of visual 
supports, behavioral and developmental 
theory, structured teaching and the 
development of functional communication 
skills.65,66 Notably, children attending this 
program showed significant improvements on 
some social and communication skills. A 
randomized control trial involving parent 
training was conducted in Australia64 and 
compared two variations of Building Block 
program that was performed at home or 
center based. This trial showed that children 
receiving centre based intervention had 
greater improvement in language 
comprehension.64 Social skill training improves 
social interaction in school-aged children.61 A 
meta-analysis of early intensive behavioral 
intervention for children with autism 
supported that this should be an intervention 
of choice for children with autism. Regrettably, 
the costs are excessive, require several 
resources to be implemented and not all 
patients may benefit from these 
interventions.67 Other approaches include 
occupational therapy that teaches skills to 
help the person live as independently as 
possible. Skills might include dressing, eating, 
bathing, and relating to people. The speech 
therapy helps to improve the person's 
communication skills. Some people are able to 
learn verbal communication skills. For others, 
however, using gestures or picture boards is 
more realistic. Indeed, the Picture Exchange 
Communication System (PECS) uses picture 
symbols to teach communication skills. The 
person is taught to use picture symbols to ask 
and answer questions and have a conversation. 
Some dietary treatments have been 
developed by reliable therapists, although 
these treatments do not have sufficient 
scientific support needed for widespread 
recommendation. Complementary and 
alternative treatments (e.g. special diets, 
chelation of heavy metals from the body, 
secretin treatment, deep pressure, etc.) are 
used by some parents and health care 
professionals despite the fact that they are 
outside of what is typically recommended by 
pediatricians.  
CONCLUDING REMARKS  
ASD is a complex disorder that has several 
etiologies involving genetic and 
environmental factors. Remarkable advances 
in the discovery of factors leading to autism 
have been achieved in the past years. However, 
the different types of modifiers that may 
exacerbate or ameliorate disease severity 
have not been identified, clearly. Such 
modifiers could include epigenetics, sex-linked 
modifiers, or environmental factors. 
Furthermore, the key architecture of ASD 
development which could be targeted for 
treatment remains still an uncharted territory. 
A better understanding and awareness of 
autism by the general population and health 
care professionals is also essential as it allows 
prompt diagnosis and early interventions that 
influence positively the development of the 
child affected by this invalidating disease. New 
hopes for children with ASD may result from 
the accomplishment of the Research Domain 
62
Malta Medical Journal     Volume 32 Issue 03 2020           
Criteria project by the National Institute of 
Mental Health that aims to explore the 
biological and psychosocial causes of ASD and 
identify new treatments strategies for 
autism.68 Thus, further work is imperatively 
needed to broaden the horizons on the causes 
and accomplish new therapeutic options for 
ASD. 
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